VCA Stocks

Novacta Biosystems, a UK-based developer of anti-infective therapeutics, has raised Gbp3.5 ($6.9 million).  Proprietary products are focused on acne and skin infections, but they also do a lot of joint research work.  This money was actually raised to target C. difficile infections:  “C. difficile infections (CDIs) are a growing and serious problem and have, for example, been associated with twice as many deaths in UK hospitals last year as MRSA. Cases of C. difficile infections, which occur in the lower digestive tract, rose by 22 per cent in the past year and affected more than 15,500 people over 65 in the first quarter of 2007. New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut.”